Phase 3 Readout~month

Phase 3 Topline: MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluat

Indication
Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease

Other upcoming events for NTLA

Phase 3 ReadoutPhase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Phase 3 ReadoutPhase 3 Topline: MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluat — NTLA Phase 3 Readout | BioSniper